Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EBIO: Epoch Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11)	1/2/2001 8:03:19 PM
From: JR	Read Replies (1) \| Respond to of 33

Tuck--Thanks for identifying your souce (Yahoo). The FSVK (Auerbach) report issued Aug. 11, 2000 projects negative earnings 9 cents/share for 2001. I don't know where Yahoo got 4 cents. An increase from 9 cents to 11 cents is significant, but nothing like an increase from 4 to 11. Auerbach estimates that when total revenues hit $14 - 22 million annually, EBIO can earn from 25 cents to 52 cents per share. Given that management has revised upward the 2000 revenue projection to $11 million during the November cc, they are getting close to profitability. Their plan to market and sell a line of probes could speed this process up, especially if their reagents, etc. are as enabling to a variety of users as Auerbach explained in his report.